

**Experiment Number:** 20601 - 04

**Test Type:** CHRONIC

**Route:** RESPIRATORY EXPOSURE WHOLE BODY

**Species/Strain:** MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Antimony trioxide

**CAS Number:** 1309-64-4

**Date Report Requested:** 12/03/2014

**Time Report Requested:** 09:59:55

**First Dose M/F:** 10/06/08 / 10/06/08

**Lab:** BNW

F1\_M3

**NTP Study Number:** C20601

**Lock Date:** 06/22/2011

**Cage Range:** ALL

**Date Range:** ALL

**Reasons For Removal:** 25022 ACCK  
25019 MSAC

25021 TSAC

25020 NATD

**Removal Date Range:** ALL

**Treatment Groups:** Include ALL

**Study Gender:** Both

**TDMSE Version:** 3.0.2.2\_002

**PWG Approval Date:** NONE

Experiment Number: 20601 - 04  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 12/03/2014  
 Time Report Requested: 09:59:55  
 First Dose M/F: 10/06/08 / 10/06/08  
 Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
------------------	---------	---------	----------	----------

## Disposition Summary

<b>Animals Initially In Study</b>	<b>60</b>	<b>60</b>	<b>60</b>	<b>60</b>
<b>Early Deaths</b>				
<b>Accidentally Killed</b>		<b>1</b>		
<b>Moribund Sacrifice</b>	<b>7</b>	<b>12</b>	<b>15</b>	<b>26</b>
<b>Natural Death</b>	<b>5</b>	<b>7</b>	<b>8</b>	<b>7</b>
<b>Survivors</b>				
<b>Terminal Sacrifice</b>	<b>38</b>	<b>30</b>	<b>27</b>	<b>17</b>
<b>Animals Examined Microscopically</b>	<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>

## ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Inflammation, Chronic Active	1 (2%)			
Gallbladder	(44)	(41)	(38)	(40)
Inflammation, Chronic	2 (5%)	1 (2%)		2 (5%)
Intestine Large, Cecum	(46)	(45)	(45)	(47)
Inflammation, Chronic Active		3 (7%)		1 (2%)
Intestine Large, Colon	(48)	(45)	(47)	(48)
Lymphoid Tissue, Hyperplasia	1 (2%)			
Intestine Large, Rectum	(47)	(42)	(45)	(48)
Intestine Small, Duodenum	(45)	(45)	(42)	(46)
Intestine Small, Ileum	(46)	(44)	(43)	(48)
Atrophy		1 (2%)		
Inflammation, Chronic Active		3 (7%)		1 (2%)
Peyer's Patch, Hyperplasia, Lymphoid	2 (4%)			2 (4%)
Intestine Small, Jejunum	(46)	(44)	(42)	(48)
Atrophy		1 (2%)		
Inflammation	1 (2%)		1 (2%)	2 (4%)
Mineralization				1 (2%)
Necrosis			1 (2%)	
Peyer's Patch, Hyperplasia, Lymphoid	1 (2%)			2 (4%)
Liver	(50)	(50)	(49)	(50)
Angiectasis	1 (2%)		1 (2%)	
Basophilic Focus	4 (8%)	3 (6%)	2 (4%)	5 (10%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Antimony trioxide

CAS Number: 1309-64-4

Date Report Requested: 12/03/2014

Time Report Requested: 09:59:55

First Dose M/F: 10/06/08 / 10/06/08

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Clear Cell Focus	14 (28%)	9 (18%)	10 (20%)	6 (12%)
Eosinophilic Focus	4 (8%)	5 (10%)	7 (14%)	7 (14%)
Eosinophilic Focus, Multiple				1 (2%)
Fatty Change			1 (2%)	
Hepatodiaphragmatic Nodule				1 (2%)
Inflammation, Chronic Active	1 (2%)	1 (2%)		3 (6%)
Mineralization	1 (2%)			
Mixed Cell Focus	1 (2%)	2 (4%)	3 (6%)	1 (2%)
Necrosis	3 (6%)	2 (4%)	1 (2%)	6 (12%)
Pigmentation				1 (2%)
Syncytial Alteration		1 (2%)	1 (2%)	
Thrombosis	1 (2%)			1 (2%)
Centrilobular, Atrophy	1 (2%)			
Centrilobular, Atrophy, Chronic		1 (2%)		
Mesentery	(7)	(4)	(4)	(5)
Cyst, Squamous				1 (20%)
Hemorrhage			1 (25%)	
Inflammation, Chronic Active			1 (25%)	
Necrosis, Fatty	3 (43%)	2 (50%)	2 (50%)	1 (20%)
Thrombosis	1 (14%)		1 (25%)	
Artery, Inflammation, Chronic Active	1 (14%)			2 (40%)
Artery, Necrosis, Chronic Active				1 (20%)
Oral Mucosa	(1)	(0)	(0)	(0)
Pharyngeal, Inflammation, Chronic Active	1 (100%)			
Pancreas	(49)	(49)	(49)	(50)
Inflammation	1 (2%)			1 (2%)
Salivary Glands	(50)	(50)	(50)	(50)
Artery, Inflammation, Chronic Active	1 (2%)			
Stomach, Forestomach	(50)	(50)	(49)	(50)
Hyperkeratosis		2 (4%)	1 (2%)	3 (6%)
Hyperplasia, Squamous	1 (2%)			3 (6%)
Inflammation, Chronic Active	2 (4%)	4 (8%)	4 (8%)	7 (14%)
Mineralization			1 (2%)	
Ulcer				2 (4%)
Stomach, Glandular	(48)	(49)	(49)	(50)
Atrophy		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Antimony trioxide

CAS Number: 1309-64-4

Date Report Requested: 12/03/2014

Time Report Requested: 09:59:55

First Dose M/F: 10/06/08 / 10/06/08

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Dysplasia, Focal	1 (2%)			
Inflammation, Chronic Active	2 (4%)	4 (8%)		1 (2%)
Mineralization	3 (6%)	2 (4%)	1 (2%)	1 (2%)
Necrosis	1 (2%)		1 (2%)	
Thrombosis			1 (2%)	
Artery, Inflammation, Chronic Active		1 (2%)		
Tooth	(14)	(14)	(14)	(6)
Dysplasia	12 (86%)	13 (93%)	12 (86%)	6 (100%)
Inflammation, Chronic Active	11 (79%)	5 (36%)	6 (43%)	3 (50%)

CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(49)	(48)	(44)
Adventitia, Inflammation, Chronic Active				1 (2%)
Media, Inflammation, Chronic Active	1 (2%)		1 (2%)	1 (2%)
Thoracic, Thrombosis		1 (2%)		
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	14 (28%)	13 (26%)	14 (28%)	19 (38%)
Necrosis			1 (2%)	
Thrombosis			2 (4%)	
Arteriole, Degeneration			1 (2%)	
Artery, Inflammation, Chronic Active	6 (12%)	10 (20%)	8 (16%)	9 (18%)
Artery, Mineralization			1 (2%)	
Atrium, Inflammation, Acute				1 (2%)
Epicardium, Fibrosis				1 (2%)
Epicardium, Inflammation, Chronic Active		2 (4%)	7 (14%)	16 (32%)
Valve, Inflammation, Chronic			1 (2%)	
Valve, Inflammation, Chronic Active		1 (2%)	2 (4%)	
Valve, Thrombosis		1 (2%)		

ENDOCRINE SYSTEM

Adrenal Cortex	(49)	(50)	(49)	(49)
Necrosis			1 (2%)	
Subcapsular, Hypertrophy		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Antimony trioxide

CAS Number: 1309-64-4

Date Report Requested: 12/03/2014

Time Report Requested: 09:59:55

First Dose M/F: 10/06/08 / 10/06/08

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Zona Fasciculata, Hypertrophy	26 (53%)	20 (40%)	15 (31%)	8 (16%)
Zona Glomerulosa, Necrosis				1 (2%)
Adrenal Medulla	(49)	(50)	(46)	(49)
Hyperplasia	5 (10%)	8 (16%)	9 (20%)	7 (14%)
Necrosis			1 (2%)	
Islets, Pancreatic	(49)	(49)	(49)	(50)
Angiectasis			1 (2%)	
Hyperplasia	4 (8%)	3 (6%)		2 (4%)
Parathyroid Gland	(27)	(32)	(26)	(33)
Pituitary Gland	(49)	(49)	(48)	(50)
Pars Distalis, Cyst	3 (6%)	3 (6%)		6 (12%)
Pars Distalis, Hyperplasia	4 (8%)	9 (18%)	8 (17%)	3 (6%)
Pars Intermedia, Hyperplasia		1 (2%)		
Thyroid Gland	(49)	(49)	(48)	(49)
Artery, Inflammation, Chronic Active		1 (2%)		

## GENERAL BODY SYSTEM

Peritoneum	(0)	(0)	(0)	(1)
------------	-----	-----	-----	-----

## GENITAL SYSTEM

Epididymis	(50)	(50)	(50)	(50)
Inflammation, Chronic Active	1 (2%)		1 (2%)	
Arteriole, Inflammation, Chronic Active	1 (2%)	1 (2%)		1 (2%)
Epithelium, Hypertrophy	1 (2%)			
Preputial Gland	(50)	(50)	(49)	(50)
Ectasia	12 (24%)	7 (14%)	15 (31%)	18 (36%)
Hyperplasia	1 (2%)			
Inflammation, Chronic Active	3 (6%)	4 (8%)	4 (8%)	2 (4%)
Prostate	(49)	(50)	(49)	(50)
Inflammation, Chronic Active		1 (2%)	1 (2%)	
Artery, Inflammation, Chronic Active	1 (2%)	1 (2%)		
Seminal Vesicle	(49)	(50)	(49)	(50)
Hyperplasia, Adenomatous	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Antimony trioxide

CAS Number: 1309-64-4

Date Report Requested: 12/03/2014

Time Report Requested: 09:59:55

First Dose M/F: 10/06/08 / 10/06/08

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Inflammation, Chronic		1 (2%)		
Testes	(49)	(49)	(50)	(50)
Degeneration	29 (59%)	28 (57%)	26 (52%)	22 (44%)
Mineralization	1 (2%)	1 (2%)		1 (2%)
Necrosis		1 (2%)		
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(49)	(50)	(48)	(50)
Hemorrhage				1 (2%)
Hyperplasia	10 (20%)	19 (38%)	27 (56%)	33 (66%)
Myelofibrosis	1 (2%)			
Necrosis	1 (2%)	1 (2%)		1 (2%)
Thrombosis			1 (2%)	1 (2%)
Lymph Node	(2)	(2)	(2)	(2)
Hyperplasia, Plasma Cell	1 (50%)			
Lymph Node, Bronchial	(30)	(43)	(47)	(41)
Ectasia		1 (2%)		
Foreign Body		34 (79%)	47 (100%)	38 (93%)
Hyperplasia, Lymphoid	2 (7%)	21 (49%)	26 (55%)	13 (32%)
Infiltration Cellular, Histiocyte		2 (5%)	4 (9%)	6 (15%)
Lymph Node, Mandibular	(27)	(26)	(28)	(26)
Foreign Body		7 (27%)	8 (29%)	16 (62%)
Hyperplasia, Lymphoid	4 (15%)	8 (31%)	6 (21%)	4 (15%)
Infiltration Cellular, Histiocyte		1 (4%)	4 (14%)	1 (4%)
Lymph Node, Mediastinal	(37)	(45)	(48)	(49)
Angiectasis			1 (2%)	1 (2%)
Foreign Body		32 (71%)	42 (88%)	48 (98%)
Hyperplasia, Lymphoid	2 (5%)	8 (18%)	17 (35%)	34 (69%)
Infiltration Cellular, Histiocyte		4 (9%)	13 (27%)	34 (69%)
Artery, Necrosis, Fibrinoid				2 (4%)
Lymph Node, Mesenteric	(48)	(47)	(47)	(50)
Angiectasis		1 (2%)		1 (2%)
Ectasia			1 (2%)	
Fibrosis	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Antimony trioxide

CAS Number: 1309-64-4

Date Report Requested: 12/03/2014

Time Report Requested: 09:59:55

First Dose M/F: 10/06/08 / 10/06/08

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Hyperplasia, Lymphoid	3 (6%)		1 (2%)	2 (4%)
Infiltration Cellular, Histiocyte				2 (4%)
Infiltration Cellular, Mixed Cell		2 (4%)		
Infiltration Cellular, Plasma Cell		4 (9%)	1 (2%)	
Infiltration Cellular, Polymorphonuclear			2 (4%)	
Inflammation, Acute			1 (2%)	
Artery, Inflammation, Chronic Active		1 (2%)		
Spleen	(49)	(50)	(50)	(50)
Angiectasis		1 (2%)		1 (2%)
Hematopoietic Cell Proliferation	13 (27%)	10 (20%)	10 (20%)	13 (26%)
Hyperplasia, Lymphoid	4 (8%)	6 (12%)	6 (12%)	3 (6%)
Necrosis			1 (2%)	
Artery, Necrosis, Fibrinoid				1 (2%)
Thymus	(41)	(38)	(43)	(39)
Cyst			1 (2%)	1 (3%)
Depletion Cellular	15 (37%)	14 (37%)	32 (74%)	32 (82%)
Thrombosis			1 (2%)	
Medulla, Hyperplasia, Lymphoid	2 (5%)	1 (3%)	4 (9%)	2 (5%)

## INTEGUMENTARY SYSTEM

Mammary Gland	(0)	(2)	(4)	(1)
Skin	(50)	(50)	(50)	(50)
Inflammation, Chronic Active	5 (10%)	2 (4%)	1 (2%)	3 (6%)
Necrosis		1 (2%)		

## MUSCULOSKELETAL SYSTEM

Bone	(50)	(50)	(49)	(50)
Necrosis		1 (2%)		
Femur, Fibro-Osseous Lesion	2 (4%)	2 (4%)	3 (6%)	2 (4%)
Maxilla, Fibro-Osseous Lesion		1 (2%)		
Maxilla, Osteomalacia				1 (2%)
Synovial Tissue, Inflammation, Chronic				1 (2%)
Skeletal Muscle	(2)	(3)	(1)	(1)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 12/03/2014  
 Time Report Requested: 09:59:55  
 First Dose M/F: 10/06/08 / 10/06/08  
 Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Degeneration Metaplasia, Cartilagenous Necrosis Artery, Inflammation, Chronic Active	1 (50%)	1 (33%) 1 (33%)	1 (100%)	

NERVOUS SYSTEM

	(50)	(50)	(50)	(50)
Brain	(50)	(50)	(50)	(50)
Hemorrhage		1 (2%)	1 (2%)	
Inflammation, Multifocal, Acute		1 (2%)		
Thrombosis		2 (4%)	1 (2%)	
Arteriole, Inflammation, Chronic Active	1 (2%)	2 (4%)		
Cerebrum, Inflammation, Acute		1 (2%)		
Cerebrum, Inflammation, Chronic				1 (2%)
Meninges, Infiltration Cellular, Lymphoid		1 (2%)	1 (2%)	
Peripheral Nerve	(1)	(1)	(0)	(0)
Degeneration	1 (100%)			
Spinal Cord	(1)	(2)	(0)	(0)

RESPIRATORY SYSTEM

	(50)	(50)	(50)	(50)
Larynx	(50)	(50)	(50)	(50)
Foreign Body		15 (30%)	29 (58%)	44 (88%)
Inflammation, Chronic Active	8 (16%)	4 (8%)	7 (14%)	11 (22%)
Artery, Inflammation, Chronic Active				1 (2%)
Respiratory Epithelium, Hyperplasia	1 (2%)	3 (6%)	15 (30%)	30 (60%)
Respiratory Epithelium, Inclusion Body Intracytoplasmic				1 (2%)
Respiratory Epithelium, Metaplasia, Squamous			8 (16%)	18 (36%)
Respiratory Epithelium, Necrosis				1 (2%)
Squamous Epithelium, Hyperplasia	2 (4%)		4 (8%)	13 (26%)
Squamous Epithelium, Necrosis				1 (2%)
Lung	(50)	(50)	(50)	(50)
Foreign Body		50 (100%)	50 (100%)	50 (100%)
Hemorrhage, Acute	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 20601 - 04

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Antimony trioxide

CAS Number: 1309-64-4

Date Report Requested: 12/03/2014

Time Report Requested: 09:59:55

First Dose M/F: 10/06/08 / 10/06/08

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Infiltration Cellular, Histiocyte	1 (2%)			
Infiltration Cellular, Lymphocyte	13 (26%)	47 (94%)	48 (96%)	45 (90%)
Inflammation, Focal, Chronic	1 (2%)			
Inflammation, Chronic Active		48 (96%)	50 (100%)	50 (100%)
Mineralization		1 (2%)		
Necrosis			1 (2%)	
Pigmentation, Focal	1 (2%)			
Proteinosis			1 (2%)	
Thrombosis	1 (2%)	1 (2%)		
Alveolar Epithelium, Hyperplasia	6 (12%)	39 (78%)	45 (90%)	49 (98%)
Alveolus, Fibrosis		12 (24%)	30 (60%)	37 (74%)
Alveolus, Infiltration Cellular, Histiocyte	2 (4%)			
Artery, Inflammation, Chronic Active	1 (2%)	1 (2%)		
Bronchiole, Epithelium, Hyperplasia		32 (64%)	44 (88%)	44 (88%)
Bronchiole, Epithelium, Goblet Cell, Metaplasia			1 (2%)	
Bronchus, Epithelium, Accumulation, Hyaline Droplet				2 (4%)
Bronchus, Epithelium, Hyperplasia		1 (2%)	1 (2%)	
Bronchus, Epithelium, Metaplasia, Squamous			1 (2%)	
Bronchus, Epithelium, Necrosis			1 (2%)	
Bronchus, Epithelium, Goblet Cell, Metaplasia				3 (6%)
Pleura, Fibrosis		36 (72%)	46 (92%)	50 (100%)
Pleura, Inflammation	1 (2%)	40 (80%)	47 (94%)	48 (96%)
Nose	(50)	(49)	(49)	(50)
Foreign Body		48 (98%)	48 (98%)	49 (98%)
Glands, Olfactory Epithelium, Accumulation, Hyaline Droplet				1 (2%)
Glands, Olfactory Epithelium, Dilatation	1 (2%)			
Glands, Olfactory Epithelium, Metaplasia, Respiratory	1 (2%)			
Nasolacrimal Duct, Hyperplasia, Squamous		1 (2%)		
Nasolacrimal Duct, Inflammation, Acute				2 (4%)
Nasolacrimal Duct, Inflammation, Chronic Active	1 (2%)	1 (2%)	2 (4%)	3 (6%)
Nasopharyngeal Duct, Inflammation, Chronic Active		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Antimony trioxide

CAS Number: 1309-64-4

Date Report Requested: 12/03/2014

Time Report Requested: 09:59:55

First Dose M/F: 10/06/08 / 10/06/08

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Olfactory Epithelium, Accumulation, Hyaline Droplet	3 (6%)	2 (4%)	4 (8%)	4 (8%)
Olfactory Epithelium, Atrophy		1 (2%)	1 (2%)	
Olfactory Epithelium, Inflammation, Acute			1 (2%)	1 (2%)
Olfactory Epithelium, Metaplasia, Respiratory	2 (4%)	4 (8%)		
Olfactory Epithelium, Necrosis				1 (2%)
Respiratory Epithelium, Accumulation, Hyaline Droplet	9 (18%)	7 (14%)	7 (14%)	12 (24%)
Respiratory Epithelium, Erosion, Acute			1 (2%)	
Respiratory Epithelium, Hyperplasia				2 (4%)
Respiratory Epithelium, Inflammation, Acute	1 (2%)	1 (2%)	3 (6%)	2 (4%)
Respiratory Epithelium, Inflammation, Chronic Active	3 (6%)	9 (18%)	9 (18%)	6 (12%)
Respiratory Epithelium, Metaplasia, Squamous		2 (4%)	1 (2%)	2 (4%)
Respiratory Epithelium, Necrosis				2 (4%)
Respiratory Epithelium, Regeneration			1 (2%)	
Respiratory Epithelium, Thrombosis				1 (2%)
Turbinate, Inflammation, Suppurative				2 (4%)
Pleura	(0)	(0)	(0)	(2)
Trachea	(49)	(50)	(50)	(50)
Foreign Body		3 (6%)	1 (2%)	20 (40%)
Inflammation, Chronic Active		1 (2%)		
Metaplasia, Squamous			1 (2%)	
Epithelium, Hyperplasia			2 (4%)	5 (10%)
Epithelium, Inclusion Body Intracytoplasmic				1 (2%)
Epithelium, Metaplasia, Squamous				1 (2%)
Glands, Cyst		1 (2%)		

## SPECIAL SENSES SYSTEM

Eye	(48)	(49)	(47)	(50)
Cataract	5 (10%)	4 (8%)	2 (4%)	2 (4%)
Hemorrhage			1 (2%)	
Retinal Detachment	1 (2%)			
Harderian Gland	(49)	(50)	(50)	(50)
Hyperplasia	1 (2%)		2 (4%)	3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04  
Test Type: CHRONIC  
Route: RESPIRATORY EXPOSURE WHOLE BODY  
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
Antimony trioxide  
CAS Number: 1309-64-4

Date Report Requested: 12/03/2014  
Time Report Requested: 09:59:55  
First Dose M/F: 10/06/08 / 10/06/08  
Lab: BNW

---

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Hypertrophy Epithelium, Hyperplasia	2 (4%) 1 (2%)		1 (2%)	
<hr/>				
URINARY SYSTEM				
Kidney	(50)	(50)	(49)	(50)
Cyst	1 (2%)	1 (2%)		
Hemorrhage			1 (2%)	
Infarct		1 (2%)	1 (2%)	1 (2%)
Inflammation, Acute	1 (2%)		1 (2%)	
Metaplasia, Osseous	1 (2%)	1 (2%)	2 (4%)	1 (2%)
Mineralization	2 (4%)			
Nephropathy	41 (82%)	39 (78%)	38 (78%)	40 (80%)
Thrombosis		1 (2%)		
Artery, Inflammation, Chronic Active		2 (4%)		1 (2%)
Glomerulus, Hyalinization			1 (2%)	
Ureter	(1)	(0)	(0)	(0)
Urinary Bladder	(50)	(50)	(48)	(50)
Calculus Gross Observation	1 (2%)			
Inflammation, Chronic Active	1 (2%)		1 (2%)	
Artery, Inflammation, Chronic Active		2 (4%)		

---

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 12/03/2014  
 Time Report Requested: 09:59:55  
 First Dose M/F: 10/06/08 / 10/06/08  
 Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
--------------------	---------	---------	----------	----------

## Disposition Summary

Animals Initially In Study	60	60	60	60
Early Deaths				
Accidentally Killed	1			
Moribund Sacrifice	10	11	16	27
Natural Death	3	8	8	8
Survivors				
Terminal Sacrifice	36	31	26	15
Animals Examined Microscopically	50	50	50	50

## ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(46)	(41)	(44)	(45)
Inflammation, Chronic		1 (2%)	1 (2%)	
Intestine Large, Cecum	(47)	(44)	(48)	(47)
Inflammation, Chronic Active		2 (5%)	2 (4%)	
Intestine Large, Colon	(47)	(47)	(49)	(47)
Necrosis			1 (2%)	
Intestine Large, Rectum	(44)	(46)	(48)	(47)
Intestine Small, Duodenum	(47)	(44)	(45)	(45)
Intestine Small, Ileum	(47)	(45)	(47)	(45)
Inflammation, Chronic Active			1 (2%)	
Peyer's Patch, Hyperplasia, Lymphoid			1 (2%)	
Intestine Small, Jejunum	(47)	(43)	(46)	(44)
Inflammation		1 (2%)		
Peyer's Patch, Hyperplasia, Lymphoid	1 (2%)			
Liver	(50)	(50)	(50)	(50)
Angiectasis	2 (4%)	1 (2%)	1 (2%)	2 (4%)
Basophilic Focus				1 (2%)
Clear Cell Focus	6 (12%)	5 (10%)	3 (6%)	2 (4%)
Cyst			1 (2%)	
Eosinophilic Focus	2 (4%)	3 (6%)	2 (4%)	
Fatty Change		2 (4%)	1 (2%)	
Hematopoietic Cell Proliferation				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Antimony trioxide

CAS Number: 1309-64-4

Date Report Requested: 12/03/2014

Time Report Requested: 09:59:55

First Dose M/F: 10/06/08 / 10/06/08

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Inflammation, Chronic Active	4 (8%)	3 (6%)	1 (2%)	2 (4%)
Mineralization		1 (2%)		
Mixed Cell Focus	1 (2%)		1 (2%)	
Necrosis	3 (6%)	2 (4%)	5 (10%)	2 (4%)
Tension Lipidosis	4 (8%)	3 (6%)	3 (6%)	
Thrombosis		1 (2%)		
Centrilobular, Fatty Change		1 (2%)		
Hepatocyte, Periportal, Hypertrophy			1 (2%)	
Mesentery	(9)	(12)	(16)	(7)
Cyst		1 (8%)		
Inflammation, Suppurative			1 (6%)	
Inflammation, Chronic				1 (14%)
Necrosis, Fatty	5 (56%)	9 (75%)	11 (69%)	4 (57%)
Artery, Inflammation, Chronic Active	2 (22%)		2 (13%)	1 (14%)
Fat, Necrosis				1 (14%)
Lymphatic, Angiectasis			1 (6%)	
Pancreas	(50)	(50)	(50)	(50)
Atrophy		3 (6%)	2 (4%)	
Hypertrophy		1 (2%)		
Inflammation			2 (4%)	
Inflammation, Chronic Active				1 (2%)
Necrosis			1 (2%)	
Artery, Inflammation, Chronic Active		1 (2%)		1 (2%)
Duct, Cyst		2 (4%)	1 (2%)	
Salivary Glands	(50)	(50)	(50)	(50)
Inflammation, Acute		1 (2%)		
Artery, Inflammation, Chronic Active			1 (2%)	1 (2%)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Hyperkeratosis	2 (4%)			
Hyperplasia, Squamous				1 (2%)
Inflammation, Chronic Active		1 (2%)		3 (6%)
Mineralization		1 (2%)		
Perforation, Chronic Active				1 (2%)
Stomach, Glandular	(50)	(49)	(50)	(50)
Inflammation, Chronic Active	1 (2%)	1 (2%)	3 (6%)	2 (4%)
Mineralization	2 (4%)	3 (6%)	2 (4%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 12/03/2014  
 Time Report Requested: 09:59:55  
 First Dose M/F: 10/06/08 / 10/06/08  
 Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Necrosis		1 (2%)		1 (2%)
Ulcer				1 (2%)
Artery, Inflammation, Chronic Active			1 (2%)	
Tongue	(0)	(1)	(0)	(0)
Hyperkeratosis		1 (100%)		
Inflammation, Chronic Active		1 (100%)		
Ulcer		1 (100%)		
Tooth	(0)	(2)	(2)	(1)
Dysplasia		1 (50%)	1 (50%)	1 (100%)
Inflammation, Chronic Active		1 (50%)		
Peridental Tissue, Mineralization			1 (50%)	

**CARDIOVASCULAR SYSTEM**

Blood Vessel	(50)	(48)	(47)	(46)
Inflammation, Chronic Active	1 (2%)		2 (4%)	
Mineralization		1 (2%)		
Thrombosis			1 (2%)	
Adventitia, Inflammation, Chronic Active			2 (4%)	1 (2%)
Media, Inflammation, Chronic Active			1 (2%)	1 (2%)
Media, Mineralization			1 (2%)	
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	11 (22%)	13 (26%)	6 (12%)	11 (22%)
Necrosis, Acute	1 (2%)			
Thrombosis		2 (4%)		
Artery, Inflammation, Chronic Active	10 (20%)	4 (8%)	11 (22%)	5 (10%)
Artery, Mineralization		1 (2%)		
Epicardium, Inflammation, Chronic Active		2 (4%)	7 (14%)	7 (14%)
Epicardium, Myocardium, Necrosis			1 (2%)	
Myocardium, Inflammation, Acute		2 (4%)	1 (2%)	
Myocardium, Inflammation, Chronic Active		1 (2%)		
Myocardium, Necrosis		1 (2%)		
Pericardium, Hyperplasia, Lymphoid			1 (2%)	
Pericardium, Inflammation, Chronic Active			1 (2%)	1 (2%)
Valve, Inflammation, Chronic Active	1 (2%)	1 (2%)	1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 12/03/2014  
 Time Report Requested: 09:59:55  
 First Dose M/F: 10/06/08 / 10/06/08  
 Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(50)	(50)	(50)	(50)
Necrosis			1 (2%)	
Zona Fasciculata, Hypertrophy	12 (24%)	16 (32%)	11 (22%)	11 (22%)
Zona Fasciculata, Necrosis			1 (2%)	
Zona Glomerulosa, Hyperplasia				1 (2%)
Adrenal Medulla	(50)	(50)	(48)	(49)
Hyperplasia	9 (18%)	8 (16%)	9 (19%)	7 (14%)
Islets, Pancreatic	(50)	(49)	(49)	(49)
Hyperplasia, Adenomatous	1 (2%)			
Parathyroid Gland	(27)	(33)	(34)	(32)
Cyst	1 (4%)			
Hypertrophy	1 (4%)			
Pituitary Gland	(49)	(50)	(50)	(50)
Pars Distalis, Angiectasis			1 (2%)	2 (4%)
Pars Distalis, Cyst	2 (4%)	1 (2%)		
Pars Distalis, Hyperplasia	15 (31%)	6 (12%)	10 (20%)	14 (28%)
Pars Nervosa, Inflammation, Acute				1 (2%)
Pars Nervosa, Thrombosis			1 (2%)	
Thyroid Gland	(48)	(50)	(50)	(50)
Inflammation, Chronic Active			1 (2%)	1 (2%)
Follicular Cell, Hyperplasia	1 (2%)			
<b>GENERAL BODY SYSTEM</b>				
Peritoneum	(0)	(0)	(1)	(0)
Inflammation, Suppurative			1 (100%)	
<b>GENITAL SYSTEM</b>				
Clitoral Gland	(48)	(44)	(47)	(42)
Inflammation, Chronic Active	1 (2%)	1 (2%)		1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 12/03/2014  
 Time Report Requested: 09:59:55  
 First Dose M/F: 10/06/08 / 10/06/08  
 Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Ovary	(50)	(49)	(50)	(50)
Angiectasis	1 (2%)		2 (4%)	1 (2%)
Cyst			1 (2%)	
Hemorrhage			1 (2%)	
Inflammation, Acute	1 (2%)		1 (2%)	1 (2%)
Inflammation, Chronic Active	1 (2%)		1 (2%)	1 (2%)
Mineralization				1 (2%)
Necrosis, Fatty				1 (2%)
Artery, Inflammation, Chronic Active			1 (2%)	
Bursa, Cyst	1 (2%)	1 (2%)	1 (2%)	3 (6%)
Follicle, Cyst	7 (14%)	11 (22%)	13 (26%)	13 (26%)
Oviduct	(1)	(0)	(0)	(0)
Uterus	(50)	(50)	(50)	(50)
Angiectasis	2 (4%)		1 (2%)	1 (2%)
Hydrometra			1 (2%)	
Inflammation, Chronic Active	1 (2%)	3 (6%)	1 (2%)	2 (4%)
Thrombosis	1 (2%)			
Ulcer				1 (2%)
Endometrial Glands, Endometrium, Hyperplasia	1 (2%)			
Endometrium, Hyperplasia, Cystic	41 (82%)	43 (86%)	44 (88%)	41 (82%)
Lymphatic, Angiectasis			1 (2%)	
Serosa, Cyst		1 (2%)		

**HEMATOPOIETIC SYSTEM**

Bone Marrow	(50)	(50)	(50)	(50)
Atrophy				1 (2%)
Hyperplasia	3 (6%)	5 (10%)	15 (30%)	28 (56%)
Myelofibrosis	1 (2%)			
Necrosis			1 (2%)	
Lymph Node	(6)	(9)	(14)	(16)
Iliac, Angiectasis		1 (11%)	1 (7%)	
Iliac, Hyperplasia				1 (6%)
Iliac, Hyperplasia, Lymphoid			1 (7%)	

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 20601 - 04

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Antimony trioxide

CAS Number: 1309-64-4

Date Report Requested: 12/03/2014

Time Report Requested: 09:59:55

First Dose M/F: 10/06/08 / 10/06/08

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Iliac, Inflammation				1 (6%)
Lumbar, Angiectasis			1 (7%)	
Lumbar, Ectasia				3 (19%)
Lumbar, Hematopoietic Cell Proliferation				1 (6%)
Lumbar, Hyperplasia, Lymphoid	1 (17%)			
Renal, Angiectasis		3 (33%)	1 (7%)	
Renal, Hyperplasia, Lymphoid	1 (17%)			1 (6%)
Lymph Node, Bronchial	(41)	(47)	(48)	(49)
Foreign Body		34 (72%)	46 (96%)	43 (88%)
Hyperplasia, Lymphoid	2 (5%)	15 (32%)	17 (35%)	11 (22%)
Infiltration Cellular, Histiocyte		2 (4%)	7 (15%)	7 (14%)
Infiltration Cellular, Plasma Cell				1 (2%)
Inflammation, Acute	1 (2%)			1 (2%)
Lymph Node, Mandibular	(41)	(28)	(38)	(39)
Angiectasis		1 (4%)		
Foreign Body		5 (18%)	9 (24%)	3 (8%)
Hyperplasia, Lymphoid	7 (17%)	1 (4%)	2 (5%)	1 (3%)
Infiltration Cellular, Histiocyte			2 (5%)	1 (3%)
Lymph Node, Mediastinal	(46)	(48)	(49)	(50)
Angiectasis		1 (2%)		1 (2%)
Foreign Body		28 (58%)	45 (92%)	44 (88%)
Hyperplasia, Lymphoid		3 (6%)	16 (33%)	18 (36%)
Infiltration Cellular, Histiocyte		6 (13%)	11 (22%)	16 (32%)
Infiltration Cellular, Plasma Cell				1 (2%)
Inflammation, Acute	1 (2%)			
Pigmentation	1 (2%)			
Arteriole, Necrosis			1 (2%)	
Artery, Inflammation, Chronic Active		1 (2%)	1 (2%)	
Medullary Sinuses, Dilatation	1 (2%)			
Lymph Node, Mesenteric	(50)	(48)	(48)	(46)
Angiectasis		2 (4%)	1 (2%)	
Hematopoietic Cell Proliferation				1 (2%)
Hyperplasia, Lymphoid		2 (4%)	3 (6%)	1 (2%)
Infiltration Cellular, Histiocyte			1 (2%)	
Infiltration Cellular, Mixed Cell		2 (4%)	1 (2%)	
Infiltration Cellular, Plasma Cell		1 (2%)		1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 12/03/2014  
 Time Report Requested: 09:59:55  
 First Dose M/F: 10/06/08 / 10/06/08  
 Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Inflammation, Chronic Necrosis, Acute	1 (2%)		1 (2%)	
Spleen	(50)	(50)	(50)	(50)
Angiectasis		1 (2%)		
Hematopoietic Cell Proliferation	17 (34%)	19 (38%)	20 (40%)	35 (70%)
Hyperplasia, Lymphoid	16 (32%)	6 (12%)	8 (16%)	7 (14%)
Inflammation, Chronic Active		1 (2%)		1 (2%)
Metaplasia, Osseous Necrosis		1 (2%)	1 (2%)	
Thymus	(47)	(49)	(49)	(49)
Angiectasis	1 (2%)	1 (2%)		
Cyst			1 (2%)	
Depletion Cellular	9 (19%)	18 (37%)	23 (47%)	29 (59%)
Foreign Body				1 (2%)
Hyperplasia, Lymphoid			1 (2%)	
Inflammation, Chronic Active	1 (2%)	1 (2%)	2 (4%)	
Medulla, Hyperplasia, Lymphoid	13 (28%)	12 (24%)	15 (31%)	16 (33%)

**INTEGUMENTARY SYSTEM**

Mammary Gland	(50)	(50)	(50)	(50)
Dilatation			1 (2%)	
Hyperplasia		2 (4%)		1 (2%)
Hypertrophy	1 (2%)	4 (8%)	3 (6%)	1 (2%)
Inflammation, Chronic Active		2 (4%)		2 (4%)
Necrosis, Acute			1 (2%)	
Skin	(50)	(50)	(50)	(50)
Hyperplasia				2 (4%)
Inflammation, Chronic Active	2 (4%)	2 (4%)	2 (4%)	4 (8%)
Ulcer				1 (2%)

**MUSCULOSKELETAL SYSTEM**

Bone	(50)	(50)	(49)	(50)
Hyperostosis			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Antimony trioxide  
 CAS Number: 1309-64-4

Date Report Requested: 12/03/2014  
 Time Report Requested: 09:59:55  
 First Dose M/F: 10/06/08 / 10/06/08  
 Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Femur, Fibro-Osseous Lesion	21 (42%)	16 (32%)	10 (20%)	6 (12%)
Maxilla, Fibro-Osseous Lesion		2 (4%)	1 (2%)	1 (2%)
Skeletal Muscle	(4)	(1)	(4)	(3)
Hemorrhage	1 (25%)			
Inflammation, Chronic			1 (25%)	
Artery, Inflammation, Chronic Active	1 (25%)			
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Compression	2 (4%)	2 (4%)	2 (4%)	1 (2%)
Demyelination	1 (2%)			1 (2%)
Necrosis, Acute				1 (2%)
Thrombosis		1 (2%)	1 (2%)	
Arteriole, Inflammation, Chronic Active	2 (4%)		2 (4%)	1 (2%)
Glial Cell, Hyperplasia	1 (2%)			
Meninges, Infiltration Cellular, Histiocyte			1 (2%)	
Meninges, Infiltration Cellular, Lymphoid	1 (2%)	2 (4%)	3 (6%)	1 (2%)
Peripheral Nerve	(3)	(0)	(2)	(1)
Sciatic, Degeneration			1 (50%)	
Spinal Cord	(4)	(0)	(2)	(1)
Hemorrhage	1 (25%)			
<b>RESPIRATORY SYSTEM</b>				
Larynx	(50)	(50)	(50)	(50)
Foreign Body		25 (50%)	39 (78%)	48 (96%)
Inflammation, Chronic Active	4 (8%)	3 (6%)	2 (4%)	4 (8%)
Mineralization		1 (2%)		
Arteriole, Inflammation, Chronic Active	1 (2%)		2 (4%)	
Artery, Inflammation, Chronic Active		1 (2%)		
Cartilage, Mineralization		2 (4%)		
Respiratory Epithelium, Hyperplasia	2 (4%)		14 (28%)	18 (36%)
Respiratory Epithelium, Metaplasia, Squamous	1 (2%)		5 (10%)	24 (48%)
Squamous Epithelium, Hyperplasia	4 (8%)	1 (2%)	1 (2%)	12 (24%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Antimony trioxide

CAS Number: 1309-64-4

Date Report Requested: 12/03/2014

Time Report Requested: 09:59:55

First Dose M/F: 10/06/08 / 10/06/08

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Lung	(50)	(50)	(50)	(50)
Foreign Body		50 (100%)	50 (100%)	50 (100%)
Hemorrhage		1 (2%)		
Infiltration Cellular, Histiocyte	1 (2%)			
Infiltration Cellular, Lymphocyte	7 (14%)	37 (74%)	37 (74%)	26 (52%)
Inflammation, Chronic Active	1 (2%)	50 (100%)	50 (100%)	50 (100%)
Thrombosis	1 (2%)	1 (2%)		1 (2%)
Alveolar Epithelium, Hyperplasia	1 (2%)	36 (72%)	49 (98%)	48 (96%)
Alveolar Epithelium, Metaplasia, Squamous		1 (2%)		2 (4%)
Alveolus, Fibrosis		13 (26%)	30 (60%)	38 (76%)
Alveolus, Infiltration Cellular, Histiocyte				1 (2%)
Alveolus, Metaplasia, Squamous			1 (2%)	
Artery, Inflammation, Acute	1 (2%)			
Bronchiole, Epithelium, Hyperplasia	1 (2%)	34 (68%)	48 (96%)	45 (90%)
Bronchiole, Epithelium, Goblet Cell, Metaplasia			1 (2%)	1 (2%)
Bronchus, Epithelium, Hyperplasia			1 (2%)	
Bronchus, Epithelium, Goblet Cell, Metaplasia				2 (4%)
Mediastinum, Inflammation, Acute	1 (2%)			
Mediastinum, Necrosis, Fatty			1 (2%)	
Pleura, Fibrosis	1 (2%)	39 (78%)	50 (100%)	50 (100%)
Pleura, Inflammation	4 (8%)	27 (54%)	42 (84%)	38 (76%)
Nose	(50)	(49)	(50)	(50)
Foreign Body	1 (2%)	44 (90%)	45 (90%)	48 (96%)
Artery, Inflammation, Chronic Active	1 (2%)			
Glands, Dilatation				1 (2%)
Glands, Olfactory Epithelium, Dilatation	1 (2%)			
Glands, Respiratory Epithelium, Accumulation, Hyaline Droplet			1 (2%)	
Lumen, Hyperkeratosis	1 (2%)			
Nasolacrimal Duct, Inflammation, Acute				1 (2%)
Nasolacrimal Duct, Inflammation, Chronic Active		1 (2%)	1 (2%)	
Olfactory Epithelium, Accumulation, Hyaline Droplet	18 (36%)	9 (18%)	12 (24%)	8 (16%)
Olfactory Epithelium, Atrophy		2 (4%)	1 (2%)	1 (2%)
Olfactory Epithelium, Metaplasia, Respiratory		1 (2%)	3 (6%)	
Olfactory Epithelium, Necrosis	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Antimony trioxide

CAS Number: 1309-64-4

Date Report Requested: 12/03/2014

Time Report Requested: 09:59:55

First Dose M/F: 10/06/08 / 10/06/08

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Respiratory Epithelium, Accumulation, Hyaline Droplet	29 (58%)	22 (45%)	25 (50%)	19 (38%)
Respiratory Epithelium, Hyperplasia				2 (4%)
Respiratory Epithelium, Inflammation, Acute	2 (4%)	7 (14%)	7 (14%)	5 (10%)
Respiratory Epithelium, Inflammation, Chronic Active	2 (4%)	3 (6%)	4 (8%)	5 (10%)
Respiratory Epithelium, Metaplasia, Squamous		3 (6%)	2 (4%)	4 (8%)
Respiratory Epithelium, Mineralization			1 (2%)	
Respiratory Epithelium, Necrosis	1 (2%)	2 (4%)		
Turbinates, Inflammation, Suppurative	1 (2%)			
Turbinates, Necrosis			1 (2%)	
Vomeroneasal Organ, Necrosis	1 (2%)			
Pleura	(0)	(2)	(0)	(2)
Necrosis, Fatty		1 (50%)		1 (50%)
Trachea	(50)	(50)	(50)	(50)
Foreign Body		7 (14%)	14 (28%)	20 (40%)
Inflammation, Chronic Active	2 (4%)	4 (8%)	4 (8%)	
Artery, Inflammation, Chronic Active	1 (2%)		1 (2%)	
Cartilage, Metaplasia, Osseous		1 (2%)		
Epithelium, Hyperplasia				1 (2%)
Epithelium, Metaplasia, Squamous			1 (2%)	1 (2%)
Epithelium, Mineralization		2 (4%)		
Glands, Inflammation, Acute		1 (2%)		
Glands, Metaplasia, Cartilagenous	2 (4%)			

## SPECIAL SENSES SYSTEM

Ear	(0)	(0)	(0)	(1)
Eye	(49)	(47)	(49)	(49)
Cataract	1 (2%)	4 (9%)	2 (4%)	4 (8%)
Cornea, Inflammation, Chronic Active				1 (2%)
Retina, Atrophy	1 (2%)			
Harderian Gland	(49)	(50)	(50)	(50)
Hyperplasia	2 (4%)			
Inflammation, Acute			1 (2%)	
Zymbal's Gland	(0)	(0)	(0)	(1)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20601 - 04  
Test Type: CHRONIC  
Route: RESPIRATORY EXPOSURE WHOLE BODY  
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
Antimony trioxide  
CAS Number: 1309-64-4

Date Report Requested: 12/03/2014  
Time Report Requested: 09:59:55  
First Dose M/F: 10/06/08 / 10/06/08  
Lab: BNW

---

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
<hr/>				
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Cyst			2 (4%)	
Infarct	1 (2%)	3 (6%)		
Inflammation, Acute		2 (4%)		
Metaplasia, Osseous	1 (2%)		2 (4%)	1 (2%)
Mineralization		1 (2%)		
Necrosis		1 (2%)		
Nephropathy	35 (70%)	30 (60%)	29 (58%)	32 (64%)
Artery, Inflammation, Chronic Active			1 (2%)	
Urinary Bladder	(50)	(50)	(50)	(50)
Hyperplasia, Lymphoid	1 (2%)		1 (2%)	
Infiltration Cellular, Lymphocyte, Focal				1 (2%)
Artery, Inflammation, Chronic Active	1 (2%)		2 (4%)	

---

\*\*\* END OF REPORT \*\*\*